Dont count on any significant pps increase until Major Exchange listing unless unexpected successful Covid vaccine or big pharma buyout. If listed we still need institutional support and favorable analysts coverage, without substantial support/volume it will be difficult to maintain exchange minimum requirements. Many vaccines in the works, limited time window to capture market interest. S1 and funding confirmation could help credibility ! The science looks promising what about the business/marketing progress??